Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with multidrug resistant HIV-1: A phase 3, multicenter, expanded access study

Emu B, Kumar PN, Mills A, Berhe M, Cash BR, Kuo KL, Anstett K. Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with multidrug resistant HIV-1: A phase 3, multicenter, expanded access study. J Acquir Immune Defic Syndr. 2025 Jun 4. doi: 10.1097/QAI.0000000000003699. Epub ahead of print. PMID: 40465394.


Related Posts